PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 8 | 3 | 195-206
Article title

Międzynarodowy konsensus dotyczący astmy u dzieci opracowany na podstawie International consensus on (ICON) pediatric asthma

Content
Title variants
EN
International consensus concerning management of asthma in children, based on International consensus on (ICON) pediatric asthma
Languages of publication
EN PL
Abstracts
EN
Throughout the world asthma is the most common chronic lower respiratory disease in childhood. There are several guidelines supporting medical decisions on paediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these, these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has proposed an international consensus on (ICON) paediatric asthma. The aim was to highlight the key information common to the existing guidelines as well as review and comment gap thus providing a concise reference. Generally the principles of paediatric asthma management are being accepted. Overall, the treatment goal is a disease control. In order to achieve this, patients and their parents should be educated to optimally manage a disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices however this goal has not yet been achieved.
PL
Astma jest najczęstszą przewlekłą chorobą dolnych dróg oddechowych u dzieci na całym świecie. Dostępne wytyczne ułatwiają podejmowanie decyzji leczniczych w populacji dziecięcej dotkniętej astmą. Postępowanie według ujednoliconych schematów niewątpliwie poprawia efekty, ale ich rozpowszechnianie i wdrażanie nadal stanowi duże wyzwanie. Międzynarodowa współpraca towarzystw medycznych (EAACI, AAAAI, ACAAI, WAO) zaowocowała wydaniem konsensusu ICON dotyczącego astmy u dzieci. Autorzy dokumentu podkreślili kluczowe informacje wspólne dla istniejących wytycznych, a także dokonali przeglądu oraz skomentowali różnice, dostarczając zwięzłych rekomendacji. Niniejsza praca systematyzuje informacje zawarte w tym dokumencie. Zasady leczenia astmy u dzieci są powszechnie akceptowane. Celem terapii jest kontrola choroby. W celu optymalnego leczenia pacjenci oraz ich rodzice powinni być odpowiednio edukowani przez pracowników służby zdrowia. Istotne są również identyfikacja i unikanie czynników wyzwalających, a także regularna ocena i monitorowanie choroby. Podstawę leczenia stanowi farmakoterapia. Optymalna farmakoterapia w większości przypadków pomaga pacjentom kontrolować objawy i zmniejszyć ryzyko zachorowania w przyszłości. Leczenie zaostrzenia jest głównym punktem rozważań terapeutycznych zależnym od stosowanego leczenia przewlekłego. Dąży się do leczenia uzależnionego od fenotypu astmy, jednak ten cel nie został jeszcze osiągnięty.
Discipline
Year
Volume
8
Issue
3
Pages
195-206
Physical description
References
  • 1. Papadopoulos N.G., Arakawa H., Carlsen K.H. i wsp.: International consensus on (ICON) pediatric asthma. Allergy 2012; 67: 976-997.
  • 2. Kupczyk M., Haahtela T., Cruz A.A., Kuna P.: Reduction of asthma burden is possible through National Asthma Plans. Allergy 2010; 65: 415-419.
  • 3. Lotvall J., Pawankar R, Wallace D.V i wsp.: We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. Allergy 2012; 67: 449-450.
  • 4. Asthma Management Handbook. National Asthma Council Australia, Melbourne, 2006. Adres: www.nation-alasthma.org.au/handbook (cytowany w marcu 2011 r.).
  • 5. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), 2011. Adres: www.ginasthma.org.
  • 6. Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger. Global Initiative for Asthma (GINA), 2009. Adres: www.ginasthma.org.
  • 7. Nishimuta T., Kondo N., Hamasaki Y. i wsp.: Japanese guideline for childhood asthma. Allergol. Int. 2011; 60: 147-169.
  • 8. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute (US), Bethesda, MD, USA 2007.
  • 9. Bacharier L.B., Boner A., Carlsen K.H. i wsp.: Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008; 63: 5-34.
  • 10. British Thoracic Society and Scottish Intercollegiate Guidelines Network: British Guideline on the Management of Asthma: A National Clinical Guideline. British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2011. Adres: www.sign.ac.uk/guidelines/fulltext/101/index.html.
  • 11. Jadad A.R., Moher M., Browman G.P i wsp.: Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. BMJ 2000; 320: 537-540.
  • 12. Yunginger J.W., Reed C.E., O’Connell E.J. i wsp.: A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. Am. Rev. Respir. Dis. 1992; 146: 888-894.
  • 13. Wennergren G., Ekerljung L., Alm B. i wsp.: Asthma in late adolescence - farm childhood is protective and the prevalence increase has levelled off. Pediatr. Allergy Immunol. 2010; 21: 806-813.
  • 14. Sackesen C., Birben E., Soyer O.U. i wsp.: The effect of CD14 C159T polymorphism on in vitro IgE synthesis and cytokine production by PBMC from children with asthma. Allergy 2011; 66: 48-57.
  • 15. Tesse R., Pandey R.C., Kabesch M.: Genetic variations in toll-like receptor pathway genes influence asthma and atopy. Allergy 2011; 66: 307-316.
  • 16. Tischer C.G., Hohmann C., Thiering E. i wsp.; ENRIE-CO consortium: Meta-analysis of mould and dampness exposure on asthma and allergy in eight European birth cohorts: an ENRIECO initiative. Allergy 2011; 66: 1570-1579.
  • 17. Sporik R., Holgate S.T., Platts-Mills T.A., Cogswell J.J.: Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N. Engl. J. Med. 1990; 323: 502-507.
  • 18. Castro-Rodriguez J.A., Garcia-Marcos L., Sanchez-Solis M. i wsp.: Olive oil during pregnancy is associated with reduced wheezing during the first year of life of the offspring. Pediatr. Pulmonol. 2010; 45: 395-402.
  • 19. Bozzetto S., Carraro S., Giordano G. i wsp.: Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy 2012; 67: 10-17.
  • 20. Martinez F.D.: New insights into the natural history of asthma: primary prevention on the horizon. J. Allergy Clin. Immunol. 2011; 128: 939-945.
  • 21. Busse WW, Lemanske R.F. Jr: Asthma. N. Engl. J. Med. 2001; 344: 350-362.
  • 22. Snijders D., Agostini S., Bertuola F. i wsp.: Markers of eosinophilic and neutrophilic inflammation in bronchoalveolar lavage of asthmatic and atopic children. Allergy 2010; 65: 978-985.
  • 23. Holgate S.T: Epithelium dysfunction in asthma. J. Allergy Clin. Immunol. 2007; 120: 1233-1244.
  • 24. Chung K.F.: Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation? Eur. Respir. J. 2000; 15: 961-968.
  • 25. Hamid Q., Tulic M.: Immunobiology of asthma. Annu. Rev. Physiol. 2009; 71: 489-507.
  • 26. Robinson D.S.: The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J. Allergy Clin. Immunol. 2004; 114: 58-65.
  • 27. Xepapadaki P, Papadopoulos N.G., Bossios A. i wsp.: Duration of postviral airway hyperresponsiveness in children with asthma: effect of atopy. J. Allergy Clin. Immunol. 2005; 116: 299-304.
  • 28. Holgate S.T., Polosa R.: The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-793.
  • 29. Fixman E.D., Stewart A., Martin J.G.: Basic mechanisms of development of airway structural changes in asthma. Eur. Respir. J. 2007; 29: 379-389.
  • 30. Watelet J.B., Van Zele T., Gjomarkaj M. i wsp.: Tissue remodelling in upper airways: where is the link with lower airway remodelling? Allergy 2006; 61: 1249-1258.
  • 31. Malmstrom K., Pelkonen A.S., Malmberg L.P. i wsp.: Lung function, airway remodelling and inflammation in symptomatic infants: outcome at 3 years. Thorax 2011; 66: 157-162.
  • 32. Bossley C.J., Fleming L., Gupta A. i wsp.: Pediatric severe asthma is characterized by eosinophilia and remodeling without Th2 cytokines. J. Allergy Clin. Immunol. 2012; 129: 974-982.
  • 33. Martinez F.D., Wright A.L., Taussig L.M. i wsp.: Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N. Engl. J. Med. 1995; 332: 133-138.
  • 34. Castro-Rodriguez J.A., Holberg C.J., Wright A.L., Martinez F.D.: A clinical index to define risk of asthma in young children with recurrent wheezing. Am. J. Respir. Crit. Care Med. 2000; 162: 1403-1406.
  • 35. Bacharier L.B., Strunk R.C., Mauger D. i wsp.: Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am. J. Respir. Crit. Care Med. 2004; 170: 426-432.
  • 36. Frey U.: Forced oscillation technique in infants and young children. Paediatr. Respir. Rev. 2005; 6: 246-254.
  • 37. Bisgaard H., Nielsen K.G.: Plethysmographic measurements of specific airway resistance in young children. Chest 2005; 128: 355-362.
  • 38. Schwartz L.B., Delgado L., Craig T. i wsp.: Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRACTALL consensus report (what the general practitioner should know about sports and allergy). Allergy 2008; 63: 953-961.
  • 39. Cockcroft D., Davis B.: Direct and indirect challenges in the clinical assessment of asthma. Ann. Allergy Asthma Immunol. 2009; 103: 363-369; quiz 369-372, 400.
  • 40. Illi S., von Mutius E., Lau S. i wsp.; Multicentre Allergy Study (MAS) group: Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet 2006; 368: 763-770.
  • 41. Dweik R.A., Boggs P.B., Erzurum S.C. i wsp.; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications: An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med. 2011; 184: 602-615.
  • 42. L0drup Carlsen K.C., Soderstrom L., Mowinckel P i wsp.: Asthma prediction in school children; the value of combined IgE-antibodies and obstructive airways disease severity score. Allergy 2010; 65: 1134-1140.
  • 43. Murray C.S., Woodcock A., Langley S.J. i wsp.; IFWIN study team: Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368: 754-762.
  • 44. Bisgaard H., Hermansen M.N., Loland L. i wsp.: Intermittent inhaled corticosteroids in infants with episodic wheezing. N. Engl. J. Med. 2006; 354: 1998-2005.
  • 45. Guilbert T.W, Morgan WJ., Zeiger R.S. i wsp.: Longterm inhaled corticosteroids in preschool children at high risk for asthma. N. Engl. J. Med. 2006; 354: 1985-1997.
  • 46. Vahlkvist S., Inman M.D., Pedersen S.: Effect of asthma treatment on fitness, daily activity and body composition in children with asthma. Allergy 2010; 65: 1464-1471.
  • 47. Durham S.R., Walker S.M., Varga E.M. i wsp.: Longterm clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 1999; 341: 468-475.
  • 48. Eng PA., Reinhold M., Gnehm H.P: Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57: 306-312.
  • 49. Jacobsen L., Niggemann B., Dreborg S. i wsp.; The PAT investigator group: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-948.
  • 50. Barnes PJ.: Inhaled glucocorticoids for asthma. N. Engl. J. Med. 1995; 332: 868-875.
  • 51. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N. Engl. J. Med. 2000; 343: 1054-1063.
  • 52. Leone F.T., Fish J.E., Szefler S.J., West S.L.: Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest 2003; 124: 2329-2340.
  • 53. Guilbert T.W!, Mauger D.T., Allen D.B. i wsp.; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute: Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. J. Allergy Clin. Immunol. 2011; 128: 956-963.
  • 54. Strunk R.C., Sternberg A.L., Szefler S.J. i wsp.; Childhood Asthma Management Program (CAMP) Research Group: Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J. Pedi-atr. 2009; 154: 682-687.
  • 55. Lipworth B.J.: Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
  • 56. Drazen J.M., Israel E., O’Byrne PM.: Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999; 340: 197-206.
  • 57. Price D., Musgrave S.D., Shepstone L. i wsp.: Leukotriene antagonists as first-line or add-on asthma-controller therapy. N. Engl. J. Med. 2011; 364: 1695-1707.
  • 58. Garcia Garcia M.L., Wahn U., Giiles L. i wsp.: Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116: 360-369.
  • 59. Stelmach I., Grzelewski T., Majak P i wsp.: Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J. Allergy Clin. Immunol. 2008; 121: 383-389.
  • 60. Ram F.S., Cates C.J., Ducharme F.M.: Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. 2005; (1): CD003137.
  • 61. Woolcock A., Lundback B., Ringdal N., Jacques L.A.: Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481-1488.
  • 62. Greening A.P., Ind P.W, Northfield M., Shaw G.: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-224.
  • 63. Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J.: Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst. Rev. 2010; (4): CD005533.
  • 64. Nelson H.S., Weiss S.T, Bleecker E.R i wsp.; SMART Study Group: The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
  • 65. Rodrigo G.J., Castro-Rodriguez J.A.: Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax 2012; 67: 342-349.
  • 66. Main C., Shepherd J., Anderson R. i wsp.: Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. Health Technol. Assess. 2008; 12: 1-174, iii-iv.
  • 67. Ducharme F.M., Ni Chroinin M., Greenstone I., Lasser-son T.J.: Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2010; (5): CD005535.
  • 68. Bisgaard H., Le Roux P, Bjamer D. i wsp.: Budesonide/ formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130: 1733-1743.
  • 69. Weinberger M., Hendeles L.: Theophylline in asthma. N. Engl. J. Med. 1996; 334: 1380-1388.
  • 70. Walker S., Monteil M., Phelan K. i wsp.: Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2006; (2): CD003559.
  • 71. Finn A., Gross G., van Bavel J. i wsp.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. 2003; 111: 278-284.
  • 72. Rodrigo G.J., Neffen H., Castro-Rodriguez J.A.: Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35.
  • 73. Kopp M.V: Role of immunmodulators in allergen-specific immunotherapy. Allergy 2011; 66: 792-797.
  • 74. Bleecker E.R, Welch M.J., Weinstein S.F. i wsp.: Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J. Allergy Clin. Immunol. 2000; 105: 1123-1129.
  • 75. Busse W, Raphael G.D., Galant S. i wsp.; Fluticasone Proprionate Clinical Research Study Group: Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J. Allergy Clin. Immunol. 2001; 107: 461-468.
  • 76. Szefler S.J., Phillips B.R., Martinez F.D. i wsp.: Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 2005; 115: 233-242.
  • 77. Bisgaard H., Skoner D., Boza M.L. i wsp.: Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr. Pul-monol. 2009; 44: 568-579.
  • 78. Ballardini N., Kull I., Lind T. i wsp.: Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort. Allergy 2012; 67: 537-544.
  • 79. De Benedictis F.M., Selvaggio D.: Use of inhaler devices in pediatric asthma. Paediatr. Drugs 2003; 5: 629-638.
  • 80. Castro-Rodriguez JA., Rodrigo G.J.: β-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J. Pediatr. 2004; 145: 172-177.
  • 81. Cates C.J., Crilly J.A., Rowe B.H.: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst. Rev. 2006: (2): CD000052.
  • 82. Pajno G.B., Barberio G., De Luca F. i wsp.: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 2001; 31: 1392-1397.
  • 83. Bernstein D.I., Wanner M., Borish L. i wsp.: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 2004; 113: 1129-1136.
  • 84. Nathan R.A., Sorkness CA, Kosinski M. i wsp.: Development of the asthma control test: a survey for assessing asthma control. J. Allergy Clin. Immunol. 2004; 113: 59-65.
  • 85. Juniper E.F., O’Byrne P.M., Guyatt G.H. i wsp.: Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14: 902-907.
  • 86. Liu A.H., Zeiger R., Sorkness C. i wsp.: Development and cross-sectional validation of the Childhood Asthma Control Test. J. Allergy Clin. Immunol. 2007; 119: 817-825.
  • 87. Murphy K.R., Zeiger R.S., Kosinski M. i wsp.: Test for respiratory and asthma control in kids (TRACK): a caregiver-completed questionnaire for preschool-aged children. J. Allergy Clin. Immunol. 2009; 123: 833-839.
  • 88. Wildfire J.J., Gergen P.J., Sorkness C.A. i wsp.: Development and validation of the Composite Asthma Severity Index - an outcome measure for use in children and adolescents. J. Allergy Clin. Immunol. 2012; 129: 694-701.
  • 89. Jackson D.J., Sykes A., Mallia P., Johnston S.L.: Asthma exacerbations: origin, effect, and prevention. J. Allergy Clin. Immunol. 2011; 128: 1165-1174.
  • 90. Papadopoulos N.G., Christodoulou I., Rohde G. i wsp.: Viruses and bacteria in acute asthma exacerbations - a GA2LEN-DARE systematic review. Allergy 2011; 66: 458-468.
  • 91. Taylor D.R., Bateman E.D., Boulet L.P. i wsp.: A new perspective on concepts of asthma severity and control. Eur. Respir. J. 2008; 32: 545-554.
  • 92. FitzGerald J.M., Shragge D., Haddon J. i wsp.: A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can. Respir. J. 2000; 7: 61-67.
  • 93. Ducharme F.M., Lemire C., Noya FJ. i wsp.: Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N. Engl. J. Med. 2009; 360: 339-353.
  • 94. Rabe K.F., Vermeire PA., Soriano J.B., Maier WC.: Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000; 16: 802-807.
  • 95. Szefler S.J.: Advancing asthma care: the glass is only half full! J. Allergy Clin. Immunol. 2011; 128: 485-494.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-8cbcbede-65c4-43c1-ae1a-8f8ecbf680fd
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.